Delivery Order SPE2DB22D9101-SPE2DB25FU7NG
- Not listed
- The Defense Logistics Agency (DLA) under the Medical Supply Chain issued a delivery order valued at $7,894.80 to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits. The award, made on August 1, 2025, with an ultimate completion date of August 22, 2025, represents a firm fixed-price delivery order with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA valued at approximately $500 million through...
- The Defense Logistics Agency awarded a $1,315.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits, with an ultimate completion date of October 8, 2025. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, which...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $15,789.60 to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its facility in Park Ridge. The award was issued on May 12, 2025, with an ultimate completion date of June 3, 2025, and carries no set-aside designation. This delivery order falls under DMS...
- The Defense Logistics Agency awarded a $6,579.00 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Mitosol 0.2 mg kits. This delivery order, issued on September 26, 2025, with an ultimate completion date of October 20, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately...
- The Defense Logistics Agency awarded a delivery order valued at $5,263.24 to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits, with an ultimate completion date of August 8, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. The contract employs firm fixed-price pricing and represents a delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $3,947.40 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Mitosol 0.2 mg kits. The contract, issued on September 18, 2025, with an ultimate completion date of October 9, 2025, utilizes a firm fixed-price structure and carries no set-aside designation. This delivery order is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $5,263.24 by the Defense Logistics Agency on August 14, 2025, for the supply of Mitosol 0.2 mg kits. The contract represents a firm fixed-price delivery order with an ultimate completion date of September 5, 2025, and carries no set-aside designation. This award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $5,263.24 to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits, with an ultimate completion date of September 12, 2025. This firm fixed-price delivery order was issued without a set-aside designation to the woman-owned small business pharmaceutical wholesaler, which is based in Park Ridge, Illinois and will perform the work at that same location. DMS Pharmaceutical Group Inc. operates under a larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $3,947.40 on September 9, 2025, for the supply of Mitosol 0.2 mg kits. The contract, which carries no set-aside designation, is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency (DLA) under the SPE2DB program, valued at $499.999 billion and extending through November...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed-price delivery order contract valued at $1,315.80 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the provision of Mitosol 0.2mg kits, a pharmaceutical product, with a period of performance through April 4, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery vehicle (IDV) contract 4600082013 with the DLA, valued at up...
- SPE2DB22D9101Indefinite Delivery Contract
- SPE2DB22D9101-SPE2DB25FU7NGDelivery Order
The Defense Logistics Agency awarded a $6,579.00 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on September 26, 2025, for Mitosol 0.2 mg kits, with an ultimate completion date of October 20, 2025. This delivery order was issued without a set-aside designation and represents a continuation of the agency's ongoing pharmaceutical supply needs. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, serves as the prime contractor and will perform the work at its Park Ridge facility. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency, valued at approximately $500 million and valid through November 2026. The IDC enables the agency to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support military health facilities nationwide. Mitosol is a mitomycin-based antimetabolite medication used in ophthalmologic and oncologic applications, and this delivery order reflects the company's established role as a critical supplier in the federal pharmaceutical supply chain for Department of Defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.6k | 9/26/25 |